PeptideStack
5.2kquestions
20kanswers
220users

Would you accept 96.4% on cagrilintide from CPC without a content assay?

Asked 1 May 2026Modified 1 min agoViewed 11k times
20

What I am working with: 96.4% · cagrilintide · CPC.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

What would you do, and what would make you change course?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
shareeditfollowflag
AH
askedanja_hellstrom13k271 May 2026
Is the comparison against a supplier certificate or against a second independent result? – jonas_ekstrom 5 months ago
8Voting to keep this open — it is more specific than it first looks. – ines_brandt 3 months ago
add a comment

5 Answers

Accepted answer first, then by votes
41

Accepted answer

96.4 per cent purity with no content figure leaves the milligram number unmeasured. Purity says 96.4 of every 100 units of detected area is cagrilintide and 3.6 is something else. Content says how many milligrams are in the glass. The two do not constrain each other: a vial can be 96.4 per cent pure and still be under label, because water and counter-ion are part of the gross mass and neither shows up as an impurity peak. If you buy one test, buy the one that changes your arithmetic.

Reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

It helps to be literal here: mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 5 Jun 2026 by s_bhattacharya — clarified the distinction between purity and content

shareimprove this answerflag
SB
answered · accepteds_bhattacharya31k3810 May 2026
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
35

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

More usefully, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
DB
answeredDr_Ingrid_Baumgartner73k5828 Jun 2026
7I would gently push back on the second point — inter-laboratory spread is wider than stated. – eighty_six_hours 5 months ago
8For what it is worth, my own independent result was within half a per cent of this. – claudia_ferrante 6 months ago
add a comment
18

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
KA
answeredkwn_analytical147k35820 Jun 2026
14

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
LS
answeredlukas_sedlacek16k182 May 2026
Two of us submitted the same lot to different laboratories and got results a tenth apart. – Dr_Yusuf_Adeyemi 8 months ago
add a comment
13

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 4 Aug 2026 by Dr_Ingrid_Baumgartner — expanded the table to cover the lower concentration

shareimprove this answerflag
DB
answeredDr_Ingrid_Baumgartner73k5814 Jul 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.